Ten years ago, Moderna (NASDAQ:MRNA) was a brand-new biotech still more than five years from advancing its first candidate into clinical testing. It was also eight years away from conducting the biggest initial public offering in biotech history.
Much has changed over the last decade. Moderna now claims a market cap of close to $30 billion. It’s a pioneer in using messenger RNA (mRNA) to treat and prevent diseases. Moderna’s mRNA-1273 ranks among the leaders in the coronavirus vaccine race.
Where will Moderna be 10 years from now? There’s no way to know for sure, but here’s one realistic possibility.
Any discussion of Moderna’s future has to begin with what could very well become the biotech’s flagship product: COVID-19 vaccine candidate mRNA-1273. Moderna hopes to file for emergency use authorization from the Food and Drug Administration for mRNA-1273 in late November.
That filing will, of course, hinge on successful late-stage testing of mRNA-1273. My prediction is that everything will go well, leading to the vaccine winning EUA before going on to secure full FDA approval.
Assuming that happens, it’s a foregone conclusion that mRNA-1273 will become a blockbuster success for Moderna. What’s less certain is exactly how much money the vaccine will make for the company. That will depend in large part on the safety and effectiveness of other coronavirus vaccine candidates.
mRNA-1273 or a potential successor could still contribute significantly to Moderna’s top line 10 years from now. I suspect that COVID-19 will follow a similar path as the seasonal flu, with people receiving vaccines at least annually. If so, Moderna’s flagship product could continue to rake in big bucks through 2030 and into the following decade.
While mRNA-1273 is the biggest story for Moderna now, my view is that the biotech could have multiple products on the market within the next 10 years. Moderna has long believed that if mRNA is successful in treating one disease, it should be able to address lots of diseases.
The company’s pipeline includes four programs in phase 2 testing that could potentially be available for sale by the end of this decade, including its cytomegalovirus (CMV) vaccine. CMV is especially problematic for babies. Close to one in 200 babies is born with CMV infection, with roughly 20% of those babies experiencing long-term health problems.
Moderna also thinks its mRNA approach could be effective in treating cancer. The company’s wholly owned mRNA-2416 program targets solid tumors and lymphoma. Moderna and Merck are testing experimental personalized cancer vaccine mRNA-4157.
mRNA could have even more applications. AstraZeneca is evaluating AZD8601, an experimental mRNA therapeutic initially developed by Moderna, in a phase 2 study for treating coronary artery disease.
There’s also a chance that some of Moderna’s programs currently in early stage testing could be on the market by 2030. If mRNA-1273 is effective against the novel coronavirus, I fully expect that Moderna could eventually become a top player in vaccines for other viral diseases, including the flu